<DOC>
	<DOCNO>NCT01308658</DOCNO>
	<brief_summary>In study participant give 800 mg darunavir , either one 800-mg tablet formulation ( G002 ) , two commercially available 400-mg tablet formulation ( F030 ) , evaluate effect , presence low-dose ritonavir fast fed condition .</brief_summary>
	<brief_title>TMC114-TiDP3-C176 - A Study Healthy Volunteers Investigating Bioequivalence Between Two Commercially Available 400-mg Tablets One New 800-mg Tablet Darunavir ( DRV ) Presence Low-dose Ritonavir Under Fed Fasted Conditions</brief_title>
	<detailed_description>Darunavir ( DRV , formerly know TMC114 ) inhibitor human immunodeficiency virus ( HIV ) protease . This study design establish bioequivalence commercially available 400-mg tablet formulation ( F030 ) one 800-mg tablet formulation DRV ( G002 ) presence low-dose ritonavir fast fed condition . This Phase I , open-label ( participant investigator know name medication give certain moment ) , randomize ( study medication assign chance ) , 2-panel , 2-way crossover study healthy volunteer assess bioequivalence DRV follow administration 2 tablet strength ( presence low-dose ritonavir ) fast fed condition . A total 124 participant participate study . Participants divide 2 panel ; 80 participant Panel 1 ( fast ) 44 Panel 2 ( feed ) . In Panel 1 , 2 subsequent session , participant receive 2 treatment fasted condition , mean Treatment A , single oral 800-mg dose DRV formulate 400-mg commercially available tablet F030 Treatment B , single oral 800-mg dose DRV formulate 800-mg tablet formulation G002 . In Panel 2 , design Panel 1 follow fed condition , 2 treatment , respectively , call Treatments C D. In panel , participant receive ritonavir 100 mg day Days 1 5 . Ritonavir administer fed condition panel except morning intake Day 3 Panel 2 administer fasting condition . A washout period least 7 day subsequent treatment observe . Safety ( blood urine test , blood pressure , pulse , electrocardiogram , physical examination ) tolerability evaluation record regular interval throughout trial . Panel 1 ( fast condition ) Panel 2 ( feed condition ) : single dose 800 mg DRV Day 3 100 mg ritonavir daily Day 1 5 . DRV formulate commercially available 400-mg tablet formulation ( F030 ) investigational 800-mg tablet formulation ( G002 ) . Ritonavir use commercially available melt-extrusion tablet contain ritonavir eq . 100 mg .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Healthy base medical evaluation include medical history , physical examination , blood test electrocardiogram Body Mass Index 18.0 30.0 kg/mÂ² nonsmoker smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month Women must postmenopausal least 2 year surgically sterile heterosexually active duration study vasectomize partner Men must agree use highly effective method birth control . Infection Hepatitis A , B , C virus infection HIV Women pregnant breastfeed History , current medical condition could impact safety participant study Previously participate multipledose study DRV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>TMC114-C176</keyword>
	<keyword>TMC114</keyword>
	<keyword>DRV</keyword>
	<keyword>HIV</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>